Biomerica, Inc. announced it has received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (GERD), Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods Technology. These patents apply to countries under the European Patent Organization (EPO), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations. This expands the company's intellectual property protection for its diagnostic-guided therapy platform.
The European market for GERD treatments exceeds $4 billion annually, while the market for Crohn’s Disease treatments is estimated at $2.5 billion annually. The European Ulcerative Colitis market was $1.5 billion in 2023 and is projected to surpass $1.9 billion by 2028. These figures highlight the substantial market potential for Biomerica's expanded inFoods applications in Europe.
Biomerica's inFoods Technology offers a personalized and non-drug approach to GI care, identifying specific food triggers to create tailored dietary plans. This approach provides an alternative to medications with potential side effects, such as proton pump inhibitors for GERD, and supports existing therapies for Crohn's and Ulcerative Colitis. The issuance of these patents is a significant milestone in Biomerica's mission to enhance patient care through personalized medical solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.